You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦制藥(03933.HK):TUL12101滴眼液臨牀試驗申請獲批
格隆匯 03-03 17:50

格隆匯3月3日丨聯邦制藥(03933.HK)公佈,公司全資附屬公司珠海聯邦制藥股份有限公司的 1 類新藥 TUL12101 滴眼液臨牀試驗申請於2023年3月2日獲中國國家藥品監督管理局批准,受理號為 CXHL2200843,CXHL2200844,CXHL2200845。

TUL12101 為公司研發的新一代小分子 RASP(活性醛)抑制劑,用於乾眼症的治療。RASP 是炎症的前細胞因子介質,通過與蛋白質上的硫醇和胺殘基結合,增強細胞因子釋放,激活炎性小體,且可與 A 類清道夫受體(SR-A1/CD204)結合,產生促炎作用。TUL12101 作為 RASP 抑制劑可共價結合遊離醛並降低過量的 RASP 水平,迅速降低眼部活性醛的含量,緩解炎症反應,打破炎症惡性循環,達到治療乾眼症的目的。目前,國內外暫無其他同機制產品上市。

本次獲批進一步豐富了公司眼科產品管線,有助於提升公司於眼科藥物領域的市場競爭力。未來,公司將持續致力於新產品研發,預期將為公司及其股東創造更大收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account